German Tier 1, Bosch together with Randox Laboratories has developed fully automated rapid test for Covid 19 that can help medical facilities such as doctors’ offices, hospitals, laboratories, and health centres make fast diagnoses.
The rapid molecular diagnostic test runs on the Vivalytic analysis device from Bosch Healthcare Solutions. “We want the Bosch rapid COVID-19 test to play a part in containing the coronavirus pandemic as quickly as possible. It will speed up the identification and isolation of infected patients,” said Dr Volkmar Denner, chairman of the board of management, Robert Bosch.
The company says the coronavirus SARS-CoV-2 is posing major challenges for healthcare systems and medical institutions worldwide. An ability to rapidly diagnose the virus is of invaluable help in curbing its exponential spread in many countries. Bosch has developed the rapid test can detect a SARS-CoV-2 coronavirus infection in patients in under two and a half hours – measured from the time the sample is taken to the time the result arrives – in just six weeks. The company says another advantage of the rapid test is that it can be performed directly at the point of care, which eliminates the need to transport samples that ends up taking valuable time. It also means patients quickly gain certainty about their state of health, while allowing infected individuals to be identified and isolated immediately.
With the tests currently in use, patients must usually wait for one to two days for a result. “Time is of the essence in the fight against coronavirus. Reliable, rapid diagnosis directly on-site with no back and forth – that is the great advantage of our solution, which we see as another example of technology that is ‘Invented for life,” added Denner.
Diagnosing ten respiratory pathogens simultaneously
The new rapid test is one of the world’s first fully automated molecular diagnostic tests that can be used directly by all medical institutions, which allows a single sample to be tested not just for Covid 19 but also for nine other respiratory diseases, including influenza A and B, simultaneously. “The special feature of the Bosch test is that it offers differential diagnosis, which saves doctors the additional time needed for further tests. It also provides them with a reliable diagnosis quickly, so they can then begin suitable treatment faster,” said Marc Meier, president of Bosch Healthcare Solutions.
The rapid Covid 19 test is the result of a collaboration between Bosch Healthcare Solutions subsidiary and the Northern Irish medical technology company Randox Laboratories. “Together with our partner Randox, we have succeeded in developing this innovative rapid test within a very short time frame, and we are now in a position to offer it to the market. The Bosch Vivalytic analysis device evaluates the test safely and reliably directly in the hospital, in the lab, or in the doctor’s office, guaranteeing the best possible protection for patients and medical staff,” added Meier. The company is currently examining how it can help doctors and nursing staff in medical facilities such as the Robert Bosch Hospital get tested promptly, so they can be fit to work for as long as possible – with no risk of infecting others.
In various laboratory tests with SARS-CoV-2, the Bosch test delivered results with an accuracy of over 95 percent. The rapid test meets the quality standards of the World Health Organisation (WHO). A sample is taken from the patient’s nose or throat using a swab. Then the cartridge, which already contains all the reagents required for the test, is inserted into the Vivalytic device for analysis. During the analysis, medical staff can devote themselves to other tasks, for example treating patients. The Vivalytic analyser is designed to be so user-friendly that even medical personnel who have not been specially trained on it can reliably perform the test. The Bosch Vivalytic analyser can perform up to ten tests in the space of 24 hours. This means it takes just 100 devices to evaluate up to 1,000 tests per day. Given the dynamic spread of the coronavirus SARS-CoV-2, laboratories are already working beyond capacity. The Bosch Vivalytic will thus help to increase available testing capacities.
The newly developed test will be available in Germany starting in April, with other markets in Europe and elsewhere to follow.